IBDEI1R9 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,29388,2)
 ;;=^5009159
 ;;^UTILITY(U,$J,358.3,29389,0)
 ;;=L40.0^^135^1361^253
 ;;^UTILITY(U,$J,358.3,29389,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29389,1,3,0)
 ;;=3^Psoriasis Vulgaris
 ;;^UTILITY(U,$J,358.3,29389,1,4,0)
 ;;=4^L40.0
 ;;^UTILITY(U,$J,358.3,29389,2)
 ;;=^5009160
 ;;^UTILITY(U,$J,358.3,29390,0)
 ;;=L40.1^^135^1361^256
 ;;^UTILITY(U,$J,358.3,29390,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29390,1,3,0)
 ;;=3^Pustulosis Psoriasis,Generalized
 ;;^UTILITY(U,$J,358.3,29390,1,4,0)
 ;;=4^L40.1
 ;;^UTILITY(U,$J,358.3,29390,2)
 ;;=^5009161
 ;;^UTILITY(U,$J,358.3,29391,0)
 ;;=L40.2^^135^1361^11
 ;;^UTILITY(U,$J,358.3,29391,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29391,1,3,0)
 ;;=3^Acrodermatitis Continua
 ;;^UTILITY(U,$J,358.3,29391,1,4,0)
 ;;=4^L40.2
 ;;^UTILITY(U,$J,358.3,29391,2)
 ;;=^5009162
 ;;^UTILITY(U,$J,358.3,29392,0)
 ;;=L40.3^^135^1361^255
 ;;^UTILITY(U,$J,358.3,29392,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29392,1,3,0)
 ;;=3^Pustulosis Palmaris et Plantaris
 ;;^UTILITY(U,$J,358.3,29392,1,4,0)
 ;;=4^L40.3
 ;;^UTILITY(U,$J,358.3,29392,2)
 ;;=^5009163
 ;;^UTILITY(U,$J,358.3,29393,0)
 ;;=L40.4^^135^1361^157
 ;;^UTILITY(U,$J,358.3,29393,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29393,1,3,0)
 ;;=3^Guttate Psoriasis
 ;;^UTILITY(U,$J,358.3,29393,1,4,0)
 ;;=4^L40.4
 ;;^UTILITY(U,$J,358.3,29393,2)
 ;;=^5009164
 ;;^UTILITY(U,$J,358.3,29394,0)
 ;;=L40.8^^135^1361^252
 ;;^UTILITY(U,$J,358.3,29394,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29394,1,3,0)
 ;;=3^Psoriasis NEC
 ;;^UTILITY(U,$J,358.3,29394,1,4,0)
 ;;=4^L40.8
 ;;^UTILITY(U,$J,358.3,29394,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,29395,0)
 ;;=L40.9^^135^1361^254
 ;;^UTILITY(U,$J,358.3,29395,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29395,1,3,0)
 ;;=3^Psoriasis,Unspec
 ;;^UTILITY(U,$J,358.3,29395,1,4,0)
 ;;=4^L40.9
 ;;^UTILITY(U,$J,358.3,29395,2)
 ;;=^5009171
 ;;^UTILITY(U,$J,358.3,29396,0)
 ;;=L50.9^^135^1361^286
 ;;^UTILITY(U,$J,358.3,29396,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29396,1,3,0)
 ;;=3^Urticaria,Unspec
 ;;^UTILITY(U,$J,358.3,29396,1,4,0)
 ;;=4^L50.9
 ;;^UTILITY(U,$J,358.3,29396,2)
 ;;=^5009204
 ;;^UTILITY(U,$J,358.3,29397,0)
 ;;=L53.8^^135^1361^147
 ;;^UTILITY(U,$J,358.3,29397,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29397,1,3,0)
 ;;=3^Erythematous Conditions NEC
 ;;^UTILITY(U,$J,358.3,29397,1,4,0)
 ;;=4^L53.8
 ;;^UTILITY(U,$J,358.3,29397,2)
 ;;=^88044
 ;;^UTILITY(U,$J,358.3,29398,0)
 ;;=L53.9^^135^1361^146
 ;;^UTILITY(U,$J,358.3,29398,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29398,1,3,0)
 ;;=3^Erythematous Condition,Unspec
 ;;^UTILITY(U,$J,358.3,29398,1,4,0)
 ;;=4^L53.9
 ;;^UTILITY(U,$J,358.3,29398,2)
 ;;=^5009210
 ;;^UTILITY(U,$J,358.3,29399,0)
 ;;=L54.^^135^1361^145
 ;;^UTILITY(U,$J,358.3,29399,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29399,1,3,0)
 ;;=3^Erythema in Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,29399,1,4,0)
 ;;=4^L54.
 ;;^UTILITY(U,$J,358.3,29399,2)
 ;;=^5009211
 ;;^UTILITY(U,$J,358.3,29400,0)
 ;;=L56.0^^135^1361^139
 ;;^UTILITY(U,$J,358.3,29400,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29400,1,3,0)
 ;;=3^Drug Phototoxic Response
 ;;^UTILITY(U,$J,358.3,29400,1,4,0)
 ;;=4^L56.0
 ;;^UTILITY(U,$J,358.3,29400,2)
 ;;=^5009214
 ;;^UTILITY(U,$J,358.3,29401,0)
 ;;=L56.1^^135^1361^138
 ;;^UTILITY(U,$J,358.3,29401,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29401,1,3,0)
 ;;=3^Drug Photoallergic Response
 ;;^UTILITY(U,$J,358.3,29401,1,4,0)
 ;;=4^L56.1
 ;;^UTILITY(U,$J,358.3,29401,2)
 ;;=^5009215
 ;;^UTILITY(U,$J,358.3,29402,0)
 ;;=L56.2^^135^1361^236
